Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1989
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Condition Intervention
Toxoplasmosis, Cerebral
HIV Infections
Drug: Pyrimethamine
Drug: Clindamycin

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Resource links provided by NLM:

Further study details as provided by NIH AIDS Clinical Trials Information Service:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions are excluded:

  • Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.

Patients with other opportunistic infections or brain diseases are excluded.

Patients with AIDS and cerebral toxoplasmosis.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002064

United States, California
Palo Alto Med Foundation
Palo Alto, California, United States, 94301
Sponsors and Collaborators
Palo Alto Medical Foundation
  More Information Identifier: NCT00002064     History of Changes
Other Study ID Numbers: 021A 
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
AIDS-Related Opportunistic Infections
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome

Additional relevant MeSH terms:
HIV Infections
Toxoplasmosis, Cerebral
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Protozoan Infections
Parasitic Diseases
Brain Abscess
Central Nervous System Protozoal Infections
Central Nervous System Parasitic Infections
Central Nervous System Infections
Clindamycin palmitate
Clindamycin phosphate
Anti-Bacterial Agents processed this record on October 25, 2016